{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:12:32Z","timestamp":1790745152535,"version":"4.1.0"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.phrs.2018.02.018","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T13:45:09Z","timestamp":1518702309000},"page":"199-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"special_numbering":"C","title":["OPA1: How much do we know to approach therapy?"],"prefix":"10.1016","volume":"131","author":[{"given":"Valentina","family":"Del Dotto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Fogazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Lenaers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Rugolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Carelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Zanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2018.02.018_bib0005","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.biocel.2009.04.013","article-title":"OPA1 functions in mitochondria and dysfunctions in optic nerve","volume":"41","author":"Lenaers","year":"2009","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0010","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/sj.cdd.4402048","article-title":"OPA1 alternate splicing uncouples an evolutionary conserved function in mitochondrial fusion from a vertebrate restricted function in apoptosis","volume":"14","author":"Olichon","year":"2007","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.phrs.2018.02.018_bib0015","first-page":"176","article-title":"The dynamin GTPase OPA1: more than mitochondria?","volume":"2013","author":"Belenguer","year":"1833","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2018.02.018_bib0020","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1242\/jcs.159186","article-title":"OPA1 processing in cell death and disease \u2013 the long and short of it","volume":"129","author":"MacVicar","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.phrs.2018.02.018_bib0025","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1083\/jcb.200704110","article-title":"OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and Yme1L","volume":"178","author":"Song","year":"2007","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0030","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1083\/jcb.200704112","article-title":"Regulation of the mitochondrial dynamin-like protein Opa1 by proteolytic cleavage","volume":"178","author":"Griparic","year":"2007","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0035","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1083\/jcb.200906084","article-title":"Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1","volume":"187","author":"Ehses","year":"2009","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0040","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1101\/gr.108696.110","article-title":"OPA1 links human mitochondrial genome maintenance to mtDNA replication and distribution","volume":"21","author":"Elachouri","year":"2011","journal-title":"Genome Res."},{"key":"10.1016\/j.phrs.2018.02.018_bib0045","doi-asserted-by":"crossref","first-page":"11288","DOI":"10.1073\/pnas.1512131112","article-title":"Cross-strand binding of TFAM to a single mtDNA molecule forms the mitochondrial nucleoid","volume":"112","author":"Kukat","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.02.018_bib0050","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/79944","article-title":"OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28","volume":"26","author":"Alexander","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2018.02.018_bib0055","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/79936","article-title":"Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy","volume":"26","author":"Delettre","year":"2000","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2018.02.018_bib0060","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/humu.22703","article-title":"Improved locus-specific database for OPA1 mutations allows inclusion of advanced clinical data","volume":"36","author":"Ferr\u00e9","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.phrs.2018.02.018_bib0065","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/hmg\/10.13.1359","article-title":"OPA1 mutations in patients with autosomal dominant optic atrophy and evidence for semi-dominant inheritance","volume":"10","author":"Pesch","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2018.02.018_bib0070","first-page":"1","article-title":"Infantile optic atrophy with dominant mode of inheritance: a clinical and genetic study of 19 Danish families","volume":"164","author":"Kjer","year":"1959","journal-title":"Acta Ophthalmol. Suppl."},{"key":"10.1016\/j.phrs.2018.02.018_bib0075","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0161-6420(84)34214-2","article-title":"Dominant optic atrophy, deafness, ptosis, ophthalmoplegia, dystaxia, and myopathy. A new syndrome","volume":"91","author":"Treft","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/j.phrs.2018.02.018_bib0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/13816818509007861","article-title":"Dominant optic nerve atrophy with progressive hearing loss and chronic progressive external ophthalmoplegia (CPEO)","volume":"5","author":"Meire","year":"1985","journal-title":"Ophthalmic Paediatr. Genet."},{"key":"10.1016\/j.phrs.2018.02.018_bib0085","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/eye.2014.37","article-title":"Treatment strategies for inherited optic neuropathies: past, present and future","volume":"28","author":"Yu-Wai-Man","year":"2014","journal-title":"Eye"},{"key":"10.1016\/j.phrs.2018.02.018_bib0090","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/ana.20681","article-title":"OPA1 R445H mutation in optic atrophy associated with sensorineural deafness","volume":"58","author":"Amati-Bonneau","year":"2005","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0095","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/S0002-9394(03)00665-2","article-title":"The association of autosomal dominant optic atrophy and moderate deafness may be due to the R445H mutation in the OPA1 gene","volume":"136","author":"Amati-Bonneau","year":"2003","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0100","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ajo.2004.06.011","article-title":"Dominant optic atrophy, sensorineural hearing loss, ptosis, and ophthalmoplegia: a syndrome caused by a missense mutation in OPA1","volume":"138","author":"Payne","year":"2004","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0105","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/brain\/awm298","article-title":"OPA1 mutations induce mitochondrial DNA instability and optic atrophy plus phenotypes","volume":"131","author":"Amati-Bonneau","year":"2008","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0110","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/brain\/awm272","article-title":"Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance","volume":"131","author":"Hudson","year":"2008","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0115","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/brain\/awq007","article-title":"Multi-system neurological disease is common in patients with OPA1 mutations","volume":"133","author":"Yu-Wai-Man","year":"2010","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0120","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1212\/01.wnl.0000289194.89359.a1","article-title":"Multiple sclerosis-like disorder in OPA1-related autosomal dominant optic atrophy","volume":"70","author":"Verny","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2018.02.018_bib0125","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/acn3.323","article-title":"A multiple sclerosis-like disorder in patients with OPA1 mutations","volume":"3","author":"Yu-Wai-Man","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0130","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/brain\/awq306","article-title":"Heterozygous OPA1 mutations in behr syndrome","volume":"134","author":"Marelli","year":"2011","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ana.24410","article-title":"Syndromic parkinsonism and dementia associated with OPA1 missense mutations","volume":"78","author":"Carelli","year":"2015","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0140","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1212\/NXG.0000000000000188","article-title":"Nonsyndromic Parkinson disease in a family with autosomal dominant optic atrophy due to OPA1 mutations","volume":"3","author":"Lynch","year":"2017","journal-title":"Neurol. Genet."},{"key":"10.1016\/j.phrs.2018.02.018_bib0145","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ymgme.2011.04.018","article-title":"Early-onset severe neuromuscular phenotype associated with compound heterozygosity for OPA1 mutations","volume":"103","author":"Schaaf","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.phrs.2018.02.018_bib0150","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1093\/brain\/awu184","article-title":"Early-onset Behr syndrome due to compound heterozygous mutations in OPA1","volume":"137","author":"Bonneau","year":"2014","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0155","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1093\/brain\/awu165","article-title":"Pure and syndromic optic atrophy explained by deep intronic OPA1 mutations and an intralocus modifier","volume":"137","author":"Bonifert","year":"2014","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0160","doi-asserted-by":"crossref","first-page":"e321","DOI":"10.1093\/brain\/awu234","article-title":"Behr syndrome with OPA1 compound heterozygote mutations","volume":"138","author":"Carelli","year":"2015","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13023-017-0641-1","article-title":"Not only dominant, not only optic atrophy: expanding the clinical spectrum associated with OPA1 mutations","volume":"12","author":"Nasca","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.phrs.2018.02.018_bib0170","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3892\/mmr.2016.5209","article-title":"Recessive optic atrophy, sensorimotor neuropathy and cataract associated with novel compound heterozygous mutations in OPA1","volume":"14","author":"Lee","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.phrs.2018.02.018_bib0175","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ejpn.2017.04.004","article-title":"Leigh-like neuroimaging features associated with new biallelic mutations in OPA1","volume":"21","author":"Rubegni","year":"2017","journal-title":"Eur. J. Paediatr. Neurol. EJPN Off. J. Eur. Paediatr. Neurol. Soc."},{"key":"10.1016\/j.phrs.2018.02.018_bib0180","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jmedgenet-2015-103361","article-title":"Fatal infantile mitochondrial encephalomyopathy, hypertrophic cardiomyopathy and optic atrophy associated with a homozygous OPA1 mutation","volume":"53","author":"Spiegel","year":"2016","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.phrs.2018.02.018_bib0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/brain\/awr323","article-title":"The MFN2 gene is responsible for mitochondrial DNA instability and optic atrophy plus phenotype","volume":"135","author":"Rouzier","year":"2012","journal-title":"Brain J. Neurol."},{"issue":"e223","key":"10.1016\/j.phrs.2018.02.018_bib0190","first-page":"1","article-title":"MFN2, a new gene responsible for mitochondrial DNA depletion, Brain","volume":"23","author":"Renaldo","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0195","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1074\/jbc.C200677200","article-title":"Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis","volume":"278","author":"Olichon","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.02.018_bib0200","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1042\/BC20070110","article-title":"Metalloprotease-mediated OPA1 processing is modulated by the mitochondrial membrane potential","volume":"100","author":"Guillery","year":"2008","journal-title":"Biol. Cell."},{"key":"10.1016\/j.phrs.2018.02.018_bib0205","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nature20555","article-title":"Multiple dynamin family members collaborate to drive mitochondrial division","volume":"540","author":"Lee","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2018.02.018_bib0210","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/hmg\/ddt600","article-title":"Functional interaction of Parkinson\u2019s disease-associated LRRK2 with members of the dynamin GTPase superfamily","volume":"23","author":"Stafa","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2018.02.018_bib0215","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.celrep.2017.06.090","article-title":"WBSCR16 is a guanine nucleotide exchange factor important for mitochondrial fusion","volume":"20","author":"Huang","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2018.02.018_bib0220","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-genet-110410-132529","article-title":"Fusion and fission: interlinked processes critical for mitochondrial health","volume":"46","author":"Chan","year":"2012","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.phrs.2018.02.018_bib0225","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1083\/jcb.201511036","article-title":"Metabolic regulation of mitochondrial dynamics","volume":"212","author":"Mishra","year":"2016","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0230","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cell.2006.06.025","article-title":"OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion","volume":"126","author":"Frezza","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2018.02.018_bib0235","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/brain\/awm335","article-title":"OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion","volume":"131","author":"Zanna","year":"2008","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0240","first-page":"737","article-title":"Role of the mitochondrial contact site and cristae organizing system in membrane architecture and dynamics","volume":"2017","author":"Rampelt","year":"1864","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2018.02.018_bib0245","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1074\/jbc.M110.171975","article-title":"ChChd3, an inner mitochondrial membrane protein, is essential for maintaining crista integrity and mitochondrial function","volume":"286","author":"Darshi","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.02.018_bib0250","doi-asserted-by":"crossref","first-page":"16064","DOI":"10.1038\/srep16064","article-title":"Mitofilin and CHCHD6 physically interact with Sam50 to sustain cristae structure","volume":"5","author":"Ding","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2018.02.018_bib0255","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1016\/j.celrep.2016.11.049","article-title":"Optic atrophy 1 is epistatic to the core MICOS component MIC60 in mitochondrial cristae shape control","volume":"17","author":"Glytsou","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2018.02.018_bib0260","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.15252\/embj.201488349","article-title":"OPA1-dependent cristae modulation is essential for cellular adaptation to metabolic demand","volume":"33","author":"Patten","year":"2014","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2018.02.018_bib0265","doi-asserted-by":"crossref","first-page":"ra10","DOI":"10.1126\/scisignal.2004374","article-title":"ROMO1 is an essential redox-dependent regulator of mitochondrial dynamics","volume":"7","author":"Norton","year":"2014","journal-title":"Sci. Signal."},{"key":"10.1016\/j.phrs.2018.02.018_bib0270","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.cmet.2015.04.020","article-title":"Mic10 oligomerization pinches off mitochondrial cristae","volume":"21","author":"Milenkovic","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2018.02.018_bib0275","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.cell.2010.02.026","article-title":"Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations","volume":"141","author":"Chen","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2018.02.018_bib0280","doi-asserted-by":"crossref","first-page":"7115","DOI":"10.1074\/jbc.M116.762567","article-title":"The short variant of the mitochondrial dynamin OPA1 maintains mitochondrial energetics and cristae structure","volume":"292","author":"Lee","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.02.018_bib0285","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1016\/j.celrep.2017.05.073","article-title":"OPA1 isoforms in the hierarchical organization of mitochondrial functions","volume":"19","author":"Del Dotto","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2018.02.018_bib0290","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/cdd.2012.128","article-title":"Loss of OPA1 disturbs cellular calcium homeostasis and sensitizes for excitotoxicity","volume":"20","author":"Kushnareva","year":"2013","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.phrs.2018.02.018_bib0295","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ceca.2014.11.008","article-title":"Mitochondrial Ca2+ uptake correlates with the severity of the symptoms in autosomal dominant optic atrophy","volume":"57","author":"F\u00fcl\u00f6p","year":"2015","journal-title":"Cell Calcium."},{"key":"10.1016\/j.phrs.2018.02.018_bib0300","first-page":"1570","article-title":"Defective mitochondrial fusion, altered respiratory function, and distorted cristae structure in skin fibroblasts with heterozygous OPA1 mutations","volume":"2012","author":"Agier","year":"1822","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2018.02.018_bib0305","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.exger.2017.09.002","article-title":"Optic atrophy 1 mediates coenzyme Q-responsive regulation of respiratory complex IV activity in brain mitochondria","volume":"98","author":"Takahashi","year":"2017","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0310","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2013.08.032","article-title":"Mitochondrial cristae shape determines respiratory chain supercomplexes assembly and respiratory efficiency","volume":"155","author":"Cogliati","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2018.02.018_bib0315","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1074\/jbc.M112.408633","article-title":"Dual function of mitochondrial Nm23-H4 protein in phosphotransfer and intermembrane lipid transfer: a cardiolipin-dependent switch","volume":"288","author":"Schlattner","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.02.018_bib0320","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/emboj.2013.124","article-title":"OPA1 promotes pH flashes that spread between contiguous mitochondria without matrix protein exchange","volume":"32","author":"Santo-Domingo","year":"2013","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2018.02.018_bib0325","doi-asserted-by":"crossref","first-page":"451","DOI":"10.15252\/embr.201642931","article-title":"L-OPA1 regulates mitoflash biogenesis independently from membrane fusion","volume":"18","author":"Rosselin","year":"2017","journal-title":"EMBO Rep."},{"key":"10.1016\/j.phrs.2018.02.018_bib0330","doi-asserted-by":"crossref","first-page":"e6867","DOI":"10.1371\/journal.pone.0006867","article-title":"Heterozygous mutation of Drosophila Opa1 causes the development of multiple organ abnormalities in an age-dependent and organ-specific manner","volume":"4","author":"Shahrestani","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2018.02.018_bib0335","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1371\/journal.pgen.0040006","article-title":"The molecular mechanisms of OPA1-mediated optic atrophy in drosophila model and prospects for antioxidant treatment","volume":"4","author":"Yarosh","year":"2008","journal-title":"PLoS Genet."},{"key":"10.1016\/j.phrs.2018.02.018_bib0340","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.112.003012","article-title":"OPA1 mutation and late-onset cardiomyopathy: mitochondrial dysfunction and mtDNA instability","volume":"1","author":"Chen","year":"2012","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2018.02.018_bib0345","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/acn3.305","article-title":"Loss of functional OPA1 unbalances redox state: implications in dominant optic atrophy pathogenesis","volume":"3","author":"Millet","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0350","article-title":"A novel ADOA-associated OPA1 mutation alters the mitochondrial function, membrane potential, ROS production and apoptosis","volume":"7","author":"Zhang","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2018.02.018_bib0355","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.cmet.2015.05.007","article-title":"The OPA1-dependent mitochondrial cristae remodeling pathway controls atrophic, apoptotic, and ischemic tissue damage","volume":"21","author":"Varanita","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2018.02.018_bib0360","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/CIRCRESAHA.117.311307","article-title":"Mitochondrial reactive oxygen species in lipotoxic hearts induce post-translational modifications of AKAP121, DRP1, and OPA1 that promote mitochondrial FissionNovelty and significance","volume":"122","author":"Tsushima","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2018.02.018_bib0365","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1101\/gad.1658508","article-title":"Mitochondrial dynamics and apoptosis","volume":"22","author":"Suen","year":"2008","journal-title":"Genes Dev."},{"key":"10.1016\/j.phrs.2018.02.018_bib0370","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.neuint.2017.04.009","article-title":"Connecting mitochondrial dynamics and life-or-death events via Bcl-2 family proteins","volume":"109","author":"Aouacheria","year":"2017","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.phrs.2018.02.018_bib0375","doi-asserted-by":"crossref","first-page":"15927","DOI":"10.1073\/pnas.0407043101","article-title":"OPA1 requires mitofusin 1 to promote mitochondrial fusion","volume":"101","author":"Cipolat","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.02.018_bib0380","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/jcp.20950","article-title":"Effects of OPA1 mutations on mitochondrial morphology and apoptosis: relevance to ADOA pathogenesis","volume":"211","author":"Olichon","year":"2007","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0385","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/embor.2010.50","article-title":"The BH3-only Bnip3 binds to the dynamin Opa1 to promote mitochondrial fragmentation and apoptosis by distinct mechanisms","volume":"11","author":"Landes","year":"2010","journal-title":"EMBO Rep."},{"key":"10.1016\/j.phrs.2018.02.018_bib0390","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.yexcr.2010.01.005","article-title":"Modulation of mitochondrial function and morphology by interaction of Omi\/HtrA2 with the mitochondrial fusion factor OPA1","volume":"316","author":"Kieper","year":"2010","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.phrs.2018.02.018_bib0395","first-page":"2088","article-title":"The survival effect of mitochondrial Higd-1a is associated with suppression of cytochrome C release and prevention of caspase activation","volume":"2011","author":"An","year":"1813","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2018.02.018_bib0400","doi-asserted-by":"crossref","first-page":"13014","DOI":"10.1073\/pnas.1307170110","article-title":"Higd-1a interacts with Opa1 and is required for the morphological and functional integrity of mitochondria","volume":"110","author":"An","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.02.018_bib0405","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cell.2006.06.021","article-title":"Mitochondrial rhomboid PARL regulates cytochrome c release during apoptosis via OPA1-dependent cristae remodeling","volume":"126","author":"Cipolat","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2018.02.018_bib0410","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1089\/ars.2010.3779","article-title":"The interplay between mitochondrial dynamics and mitophagy","volume":"14","author":"Twig","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.phrs.2018.02.018_bib0415","article-title":"Mammalian mitophagy \u2013 from in vitro molecules to in vivo models","author":"Rodger","year":"2017","journal-title":"FEBS J."},{"key":"10.1016\/j.phrs.2018.02.018_bib0420","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1089\/ars.2010.3799","article-title":"Targeting mitochondrial dysfunction: role for PINK1 and parkin in mitochondrial quality control","volume":"14","author":"Narendra","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.phrs.2018.02.018_bib0425","doi-asserted-by":"crossref","first-page":"19094","DOI":"10.1074\/jbc.M111.322933","article-title":"Microtubule-associated protein 1 light chain 3 (LC3) interacts with Bnip3 protein to selectively remove endoplasmic reticulum and mitochondria via autophagy","volume":"287","author":"Hanna","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2018.02.018_bib0430","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/ncb2422","article-title":"Mitochondrial outer-membrane protein FUNDC1 mediates hypoxia-induced mitophagy in mammalian cells","volume":"14","author":"Liu","year":"2012","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0435","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/sj.emboj.7601963","article-title":"Fission and selective fusion govern mitochondrial segregation and elimination by autophagy","volume":"27","author":"Twig","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2018.02.018_bib0440","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/ncb2220","article-title":"During autophagy mitochondria elongate, are spared from degradation and sustain cell viability","volume":"13","author":"Gomes","year":"2011","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0445","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/jnc.13894","article-title":"OPA1 haploinsufficiency induces a BNIP3-dependent decrease in mitophagy in neurons: relevance to Dominant Optic Atrophy","volume":"140","author":"Moulis","year":"2017","journal-title":"J. Neurochem."},{"key":"10.1016\/j.phrs.2018.02.018_bib0450","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1212\/WNL.0000000000003491","article-title":"Dysregulated mitophagy and mitochondrial organization in optic atrophy due to OPA1 mutations","volume":"88","author":"Liao","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.phrs.2018.02.018_bib0455","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.13149","article-title":"Autophagy controls the pathogenicity of OPA1 mutations in dominant optic atrophy","author":"Kane","year":"2017","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.phrs.2018.02.018_bib0460","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1167\/iovs.08-2913","article-title":"OPA1 deficiency associated with increased autophagy in retinal ganglion cells in a murine model of dominant optic atrophy","volume":"50","author":"White","year":"2009","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.phrs.2018.02.018_bib0465","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/brain\/aws303","article-title":"The human OPA1delTTAG mutation induces premature age-related systemic neurodegeneration in mouse","volume":"135","author":"Sarzi","year":"2012","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0470","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1080\/15548627.2016.1151580","article-title":"Mitophagy receptor FUNDC1 regulates mitochondrial dynamics and mitophagy","volume":"12","author":"Chen","year":"2016","journal-title":"Autophagy"},{"key":"10.1016\/j.phrs.2018.02.018_bib0475","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1128\/MCB.01483-13","article-title":"SIRT3 deacetylates and activates OPA1 to regulate mitochondrial dynamics during stress","volume":"34","author":"Samant","year":"2014","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0480","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1038\/onc.2016.425","article-title":"SIRT4 inhibits malignancy progression of NSCLCs, through mitochondrial dynamics mediated by the ERK-Drp1 pathway","volume":"36","author":"Fu","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2018.02.018_bib0485","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.18632\/aging.101307","article-title":"SIRT4 interacts with OPA1 and regulates mitochondrial quality control and mitophagy","volume":"9","author":"Lang","year":"2017","journal-title":"Aging (Milano)"},{"key":"10.1016\/j.phrs.2018.02.018_bib0490","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/15548627.2015.1009778","article-title":"SIRT5 regulation of ammonia-induced autophagy and mitophagy","volume":"11","author":"Polletta","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.phrs.2018.02.018_bib0495","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.molcel.2016.01.028","article-title":"The mitochondrial basis of aging","volume":"61","author":"Sun","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.phrs.2018.02.018_bib0500","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/brain\/awr330","article-title":"Opa1 is essential for retinal ganglion cell synaptic architecture and connectivity","volume":"135","author":"Williams","year":"2012","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0505","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cmet.2017.04.021","article-title":"Age-associated loss of OPA1 in muscle impacts muscle mass, metabolic homeostasis, systemic inflammation, and epithelial senescence","volume":"25","author":"Tezze","year":"2017","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2018.02.018_bib0510","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1111\/acel.12649","article-title":"Mitofusin 1 and optic atrophy 1 shift metabolism to mitochondrial respiration during aging","volume":"16","author":"Son","year":"2017","journal-title":"Aging Cell"},{"key":"10.1016\/j.phrs.2018.02.018_bib0515","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1038\/emboj.2011.365","article-title":"Optic atrophy 1 is an A-kinase anchoring protein on lipid droplets that mediates adrenergic control of lipolysis","volume":"30","author":"Pidoux","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2018.02.018_bib0520","first-page":"812","article-title":"Targeted metabolomics reveals early dominant optic atrophy signature in optic nerves of opa1 delTTAG\/+ mice, investig","volume":"58","author":"Chao de la Barca","year":"2017","journal-title":"Opthalmol. Vis. Sci."},{"key":"10.1016\/j.phrs.2018.02.018_bib0525","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1083\/jcb.201308006","article-title":"The i-AAA protease YME1L and OMA1 cleave OPA1 to balance mitochondrial fusion and fission","volume":"204","author":"Anand","year":"2014","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0530","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ncb3560","article-title":"Molecular basis of selective mitochondrial fusion by heterotypic action between OPA1 and cardiolipin","volume":"19","author":"Ban","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0535","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/emboj.2009.89","article-title":"SLP-2 is required for stress-induced mitochondrial hyperfusion","volume":"28","author":"Tondera","year":"2009","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2018.02.018_bib0540","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00109-015-1359-y","article-title":"Restoration of Opa1-long isoform inhibits retinal injury-induced neurodegeneration","volume":"94","author":"Sun","year":"2016","journal-title":"J. Mol. Med. Berl. Ger."},{"key":"10.1016\/j.phrs.2018.02.018_bib0545","first-page":"317","article-title":"Adeno-associated virus (AAV) as a vector for gene therapy, BioDrugs clin","volume":"31","author":"Naso","year":"2017","journal-title":"Immunother. Biopharm. Gene Ther."},{"key":"10.1016\/j.phrs.2018.02.018_bib0550","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/hum.2016.040","article-title":"Advances in gene therapy for diseases of the eye","volume":"27","author":"Petit","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.phrs.2018.02.018_bib0555","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00401-016-1625-2","article-title":"A neurodegenerative perspective on mitochondrial optic neuropathies","volume":"132","author":"Yu-Wai-Man","year":"2016","journal-title":"Acta Neuropathol. (Berl.)"},{"key":"10.1016\/j.phrs.2018.02.018_bib0560","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ophtha.2012.11.048","article-title":"Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with leber congenital amaurosis type 2","volume":"120","author":"Testa","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.phrs.2018.02.018_bib0565","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65 \u2013mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2018.02.018_bib0570","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0140-6736(16)30371-3","article-title":"Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial","volume":"388","author":"Bennett","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2018.02.018_bib0575","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.crvi.2013.11.011","article-title":"Gene therapy for mitochondrial diseases: leber Hereditary Optic Neuropathy as the first candidate for a clinical trial","volume":"337","author":"Cwerman-Thibault","year":"2014","journal-title":"C. R. Biol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0580","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.cmet.2015.04.016","article-title":"Opa1 overexpression ameliorates the phenotype of two mitochondrial disease mouse models","volume":"21","author":"Civiletto","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2018.02.018_bib0585","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1093\/brain\/awm005","article-title":"A splice site mutation in the murine Opa1 gene features pathology of autosomal dominant optic atrophy","volume":"130","author":"Alavi","year":"2007","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0590","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/hmg\/ddm079","article-title":"Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function","volume":"16","author":"Davies","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2018.02.018_bib0595","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1136\/bjophthalmol-2015-308329","article-title":"Genetic manipulation for inherited neurodegenerative diseases: myth or reality?","volume":"100","author":"Yu-Wai-Man","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0600","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.phrs.2018.02.018_bib0605","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1126\/science.1232033","article-title":"RNA-guided human genome engineering via cas9","volume":"339","author":"Mali","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.phrs.2018.02.018_bib0610","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/ICU.0000000000000359","article-title":"CRISPR applications in ophthalmologic genome surgery","volume":"28","author":"Cabral","year":"2017","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2016.05.001","article-title":"Genome engineering in ophthalmology: application of CRISPR\/Cas to the treatment of eye disease","volume":"53","author":"Hung","year":"2016","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.phrs.2018.02.018_bib0620","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1167\/iovs.16-19316","article-title":"AAV-Mediated CRISPR\/Cas gene editing of retinal cells In vivo","volume":"57","author":"Hung","year":"2016","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.phrs.2018.02.018_bib0625","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/mt.2015.220","article-title":"In vivo CRISPR\/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa","volume":"24","author":"Bakondi","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.phrs.2018.02.018_bib0630","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nm.4313","article-title":"Refining strategies to translate genome editing to the clinic","volume":"23","author":"Cornu","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2018.02.018_bib0635","series-title":"Cochrane Database Syst. Rev.","article-title":"Treatment for mitochondrial disorders","author":"Pfeffer","year":"2012"},{"key":"10.1016\/j.phrs.2018.02.018_bib0640","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/archneurol.2011.2972","article-title":"Effect of EPI-743 on the clinical course of the mitochondrial disease leber hereditary optic neuropathy","volume":"69","author":"Sadun","year":"2012","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0645","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1093\/brain\/awr180","article-title":"Idebenone treatment in Leber\u2019s hereditary optic neuropathy","volume":"134","author":"Carelli","year":"2011","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0650","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1093\/brain\/awr170","article-title":"A randomized placebo-controlled trial of idebenone in Leber\u2019s hereditary optic neuropathy","volume":"134","author":"Klopstock","year":"2011","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0655","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.neuroscience.2016.01.042","article-title":"A randomized, placebo-controlled trial of the benzoquinone idebenone in a mouse model of OPA1-related dominant optic atrophy reveals a limited therapeutic effect on retinal ganglion cell dendropathy and visual function","volume":"319","author":"Smith","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2018.02.018_bib0660","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.1093\/brain\/aws280","article-title":"Idebenone treatment in patients with OPA1-mutant dominant optic atrophy","volume":"136","author":"Barboni","year":"2013","journal-title":"Brain J. Neurol."},{"key":"10.1016\/j.phrs.2018.02.018_bib0665","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cmet.2015.06.006","article-title":"Redox homeostasis and mitochondrial dynamics","volume":"22","author":"Willems","year":"2015","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2018.02.018_bib0670","first-page":"544","article-title":"Emerging concepts in the therapy of mitochondrial disease","volume":"2015","author":"Viscomi","year":"1847","journal-title":"Biochim. Biophys. Acta BBA \u2013 Bioenerg."},{"key":"10.1016\/j.phrs.2018.02.018_bib0675","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cell.2014.12.019","article-title":"Glial lipid droplets and ROS induced by mitochondrial defects promote neurodegeneration","volume":"160","author":"Liu","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2018.02.018_bib0680","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1126\/science.1244360","article-title":"mTOR inhibition alleviates mitochondrial disease in a mouse model of Leigh syndrome","volume":"342","author":"Johnson","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.phrs.2018.02.018_bib0685","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1073\/pnas.1404651111","article-title":"Transcellular degradation of axonal mitochondria","volume":"111","author":"Davis","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2018.02.018_bib0690","doi-asserted-by":"crossref","first-page":"R139","DOI":"10.1093\/hmg\/ddx273","article-title":"Optic neuropathies: the tip of the neurodegeneration iceberg","volume":"26","author":"Carelli","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.phrs.2018.02.018_bib0695","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.phrs.2017.02.005","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2018.02.018_bib0700","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/s41598-018-20838-8","article-title":"OPA1 gene therapy prevents retinal ganglion cellloss in a dominant optic atrophy mouse model","volume":"8","author":"Sarzi","year":"2018","journal-title":"Sci. Rep."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817316171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817316171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:57:30Z","timestamp":1760911050000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817316171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":140,"alternative-id":["S1043661817316171"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.02.018","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"OPA1: How much do we know to approach therapy?","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}